Company: OXBRW
Filing Date: 2025-03-26
Form Type: 10-K
Source: 0001641172-25-000736
Chunk: 94

Company: OXBRIDGE RE HOLDINGS Ltd
Filing Date: 2025-03-26
Form: 10-K
Item: Item 13
Chunk 94
---
 (or the Company) and shall have no preemptive right or conversion rights. The Participation Shares solely
confer contractual rights against SurancePlus as contained in the PSIC. At the offering’s commencement, up to an aggregate of one
million (1,000,000) Participation Shares will be issued, represented by digital tokens labelled “ZetaCat Re” and “EtaCat
Re”, representing high yield and balanced yield tokens, respectively. The quantity of Participation Shares to be issued in subsequent
years of 2026, and 2027, shall be disclosed prior to their issuances. At the start of the offering, the Participation Shares will be
offered at an initial price of $10.00 per Participation Share, with a 5% and 10% discount per Participation Share for investments above
$50,000 and $100,000, respectively.

The
net proceeds from the offer and sale of the Participation Shares will be used by SurancePlus to purchase one or more participating notes
of Oxbridge Re NS, an affiliated Cayman Islands licensed reinsurance entity, and the proceeds from the sale of such participating notes
will be invested in collateralized reinsurance contracts to be underwritten by Oxbridge Re NS. The holders of the Participation Shares
will generally be entitled to proceeds from the payment of the participating notes in the amount of a preferred return equal to the initial
Participation Share price, plus 20%, and then 80% of any proceeds in excess of the amount necessary to pay the preferred return.

The
Securities have not been registered under the Securities Act or any state or
other securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable
exemption from registration requirements or a transaction not subject to the registration requirements of the Securities Act or any state
or other securities laws. The Securities will be sold in a transaction exempt from registration under the Securities Act and will be
sold only to persons reasonably believed to be accredited investors in the United States under SEC Rule 506(c) under the Securities Act
and outside the United States only to non-U.S. persons in accordance with Regulation S under the Securities Act.

F-30